Symptom Monitoring Using Patient-Report to Improve Medication Use

Launched by MEDICAL COLLEGE OF WISCONSIN · Jan 3, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on helping women with early-stage hormone-positive breast cancer stay on their medication, known as endocrine therapy, after their initial treatments. The study aims to understand how tracking symptoms through monthly surveys can help improve medication use. Participants will receive recommendations from specialized cancer pharmacists based on the symptoms they report, which can help make it easier for them to continue taking their medications daily.

To be eligible for this study, participants need to be women aged 18 or older who have been diagnosed with stage 1-3 hormone receptor-positive breast cancer. They should also be recommended to continue their endocrine therapy for at least two more years and have had some difficulties in sticking to their medication plan in the past. Participants will be asked to communicate in either English or Spanish and should be able to understand and sign a consent form. This study is not yet recruiting, but it aims to provide support and improve medication adherence for those at risk of not taking their prescribed treatments.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Cisgender women assigned female at birth
• • Age 18 years or older
• • Stage 1-3 hormone receptor-positive breast cancer
• • 1. Premenopausal patients being treated with GNRH agonist/antagonist to induce menopause are eligible
• • 2. Patients who received treatment with CDK 4/6 inhibitors are eligible
• • Recommended to continue AET for ≥2 additional years after enrollment
• • Low adherence defined as prescription fills with a proportion of days covered (PDC) of \<80%, examined over all fills during the 2 years prior to date of eligibility review since the first AET prescription/data of AET start OR unable to calculate adherence
• • Verbal fluency in English or Spanish
• • Ability to understand informed consent and the willingness to sign it
• Exclusion Criteria:
• • Unable to verbalize comprehension of study or impaired decision-making
• • Known distant metastatic disease
• • Not receiving breast cancer care or AET prescription from provider at participating site
• • Evidence that an oncology provider discontinued their AET
• • Pregnant or trying to get pregnant
• • Facility-administered medications (i.e., nursing home, home healthcare agency)